ViroLogic to Host Panel on Personalized Medicine at BIO 2004
June 03 2004 - 8:00AM
PR Newswire (US)
ViroLogic to Host Panel on Personalized Medicine at BIO 2004 SOUTH
SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- ViroLogic,
Inc. (NASDAQ:VLGC) today announced that Bill Young, Chairman and
CEO, will moderate a panel entitled "Making Personalized Medicine a
Reality" at BIO 2004 on Tuesday, June 8, 2004, 4:00 - 5:30 p.m. EDT
in Room 2005 West Building, 747 Howard Street in San Francisco. The
panel will also feature executives from other leading biotechnology
companies focused on personalized medicine for cancer, infectious
and other serious diseases. The panel includes: -- Gordon Ringold,
Co-founder, Chairman & CEO, SurroMed, Inc. -- Steven Shak,
M.D., Chief Medical Officer, Genomic Health, Inc. -- Sharat Singh,
Ph.D., Chief Technical Officer, ACLARA Biosciences, Inc. --
Jeannette Whitcomb, Ph.D., Vice President, Operations, ViroLogic,
Inc. -- Emily Winn-Deen, Senior Director, Genomics Business, Roche
Molecular Diagnostics "Tailoring therapy to the individual genetic
make-up of the patient or the disease-causing agent maximizes the
likelihood that treatment will be not only successful, but also
potentially more cost-effective," said Young. "Informed and
judicious use of drugs can save the health-care system millions of
dollars each year. However, the promise of personalized medicine is
dependent on the use of diagnostic and disease-monitoring
technologies to match the right patient with the right drug." This
panel will explore current examples of these technologies and what
the industry expects to see in the near future. Interviews and
one-on-one briefings with panel participants are available upon
request by contacting Carolyn Bumgardner Wang at 415-362-5018 or .
About ViroLogic ViroLogic (the "Company") is a biotechnology
company advancing individualized medicine by discovering,
developing and marketing innovative products to guide and improve
treatment of serious infectious diseases such as AIDS and
hepatitis. The Company's products are designed to help doctors
optimize treatment regimens for their patients that lead to better
outcomes and reduced costs. The Company's technology is also being
used by numerous biopharmaceutical companies to develop new and
improved antiviral therapeutics and vaccines targeted at emerging
drug-resistant viruses. More information about the Company and its
technology can be found on its web site at
http://www.virologic.com/ . Certain statements in this press
release are forward-looking, including statements relating to
personalized medicine. These forward-looking statements are subject
to risks and uncertainties and other factors, which may cause
actual results to differ materially from the anticipated results or
other expectations expressed in such forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks that the Company's products may not perform in the same
manner as indicated in this press release, whether ViroLogic
successfully introduces new products, whether others introduce
competitive products, the risk that the Company's products for
patient testing may not continue to be accepted or that increased
demand from drug development partners may not develop as
anticipated, the risk that gross margins may not increase as
expected, the risk that ViroLogic may not continue to realize
anticipated benefits from its cost-cutting measures, the timing of
pharmaceutical company clinical trials, whether payors will
authorize reimbursement for its products, whether the FDA or any
other agency will decide to regulate ViroLogic's products or
services, whether the Company will encounter problems or delays in
automating its processes, whether ViroLogic successfully introduces
new products, whether others introduce competitive products,
whether intellectual property underlying the Company's PhenoSense
technology is adequate, whether licenses to third party technology
will be available, whether ViroLogic is able to build brand loyalty
and expand revenues, and whether ViroLogic will be able to raise
sufficient capital when required. For a discussion of other factors
that may cause ViroLogic's actual events to differ from those
projected, please refer to the Company's most recent annual report
on Form 10-K and quarterly reports on Form 10-Q, as well as other
subsequent filings with the Securities and Exchange Commission.
DATASOURCE: ViroLogic, Inc. CONTACT: Karen Wilson, CFO of
ViroLogic, Inc., +1-650-624-4164, or Web site:
http://www.virologic.com/
Copyright
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Oct 2023 to Oct 2024